Alkermes' alixorexton meets dual primary endpoints in Phase 2 narcolepsy type 2 study

Alkermes plc.

Alixorexton (10, 14, 18 mg) showed statistically significant improvements vs placebo on MWT and ESS at week 8.
14 mg and 18 mg doses achieved statistical significance on MWT (p<0.05); 18 mg dose on ESS (p<0.05).
Drug was generally well tolerated; most common TEAEs were pollakiuria, insomnia, urinary urgency, dizziness, headache.
No serious TEAEs, no safety signals in hepatic, renal, vitals, ECGs, or ophthalmic exams.
Phase 3 program for narcolepsy type 1 and type 2 expected to initiate in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.